选择语言

CHO/Human uPAR Stable Cell Line

用户评价
货号-规格
价格
Qty.
SCCHO-ATP152-2Vials (1Vial X 2)
询价
合计0件 产品金额¥ 0

产品详情

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • 描述(Description)

    The CHO/Human uPAR Stable Cell Line was engineered to express the receptor full length human uPAR (Gene ID: 5329), used to mimic cancer target cells. Surface expression of human uPAR was confirmed by flow cytometry.

  • 应用说明(Application)

    • Useful for cell-based uPAR binding assay

  • 生长特性(Growth Properties)

    Adherent

  • 筛选标记(Selection Marker)

    Puromycin (2 μg/mL)

  • 培养基(Complete Growth Medium)

    F-12K + 10% FBS

  • 冻存液(Freeze Medium)

    Serum-free cell cryopreservation medium

  • 装量(Quantity)

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • 存储(Storage)

    Frozen in liquid nitrogen.

  • 支原体检测(Mycoplasma Testing)

    Negative

  • 无菌检测(Sterility Testing)

    Negative

  • 使用说明(Instructions for Use)

    See data sheet for detailed culturing and assay protocol.

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • Receptor Assay

     uPAR FACS

    Expression analysis of human uPAR on CHO/Human uPAR Stable Cell Line by FACS.
    Cell surface staining was performed on CHO/Human uPAR Stable Cell Line or negative control cell using PE-labeled anti-human uPAR antibody.

    Protocol
*如有相关细胞池需求请联系我们

用户评价
发表评论

背景介绍

Urokinase plasminogen activator surface receptor (U-PAR) is also known as PLAUR, Monocyte activation antigen Mo3, CD antigen CD87. PLAUR contains three UPAR/Ly6 domains. U-PAR is expressed in neurons of the rolandic area of the brain (at protein level) and is also expressed in the brain. PLAUR / CD87 interacts with MRC2, SRPX2 and SORL1. PLAUR / UPAR acts as a receptor for urokinase plasminogen activator and plays a role in localizing and promoting plasmin formation. U-PAR mediates the proteolysis-independent signal transduction activation effects of U-PA.

重要声明

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

前沿进展

 
药物研发进展
  • 英文全称:

    Urokinase plasminogen activator surface receptor

  • 中文全称:

    尿激酶型纤溶酶原激活物表面受体

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    7 详情

  • 最高研发阶段:

    临床三期

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍
  • 重要声明